Dr. Paul Harch – The Oxygen Revolution: Hyperbaric Oxygen Therapy
Dr. Harch joins Sound Health Radio to share what his research has revealed about HBOT and how it can help those suffering from brain injury or diseases such as: stroke, autism, cerebral palsy, Alzheimer’s, Parkinson’s, and more! Dr. Paul Harch is a...Legally blind Northstate woman regains her vision through oxygen therapy
When artist, Darcy Wilson’s right eye suffered from 1/3 vision loss after a stroke, her Ophthalmologist urgently sent her over to the Mercy Medical Center’s Wound, Healing and Hyperbaric Center to immediately start hyperbaric oxygen therapy (HBOT)....Study Shows Hyperbaric Oxygen Therapy (HBOT) Protocols Can Improve Cognitive Function in Stroke Patients
One of the largest hyperbaric chamber centers in the world, The Sagol Center for Hyperbaric Medicine and Research at Shamir Medical Center, announced study results which indicate that HBOT (hyperbaric oxygen therapy) produced significant improvement in most cognitive...The Nobel Prize in Physiology or Medicine 2019 – Sensing oxygen levels
The AC133 antigen is a novel antigen selectively expressed on a subset of CD34+ cells in human fetal liver, bone marrow, and blood as demonstrated by flow cytometric analyses. In this study, we have further assessed the expression of AC133 on CD34+ cells in hemopoietic samples and found that there was a highly significant difference between normal bone marrow and cord blood versus aphereses (p <0.0001) but not between bone marrow and cord blood. Most of the clonogenic cells (67%) were contained in the CD34+AC133+ fraction. Compared with cultures of the CD34+AC133- cells, generation of progenitor cells in long-term culture on bone marrow stroma was consistently 10- to 100-fold higher in cultures initiated with CD34+AC133+ cells and was maintained for the 8-10 weeks of culture.